Q-omics provides the consensus-scored STK39 profile across patient tissues and cancer cell-line models. STK39 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, STK39 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, STK39 RNA expression shows 20,613 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, LUAD, and ACC as cancer lineages where STK39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK39 survival associations across molecular data types. STK39 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK39 RNA expression–survival associations across cancer types. High STK39 expression shows unfavorable associations in MESO, ACC, LIHC, UVM and ESCA, but favorable associations in BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for STK39 RNA expression.
This table summarizes STK39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for STK39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK39 shows lower tumor expression in HNSC and higher tumor expression in LUAD, KIRP, KIRC, KICH and LIHC. The LUAD box plot shows higher STK39 RNA expression in tumor versus normal tissue (log2 FC = +1.911, t-test p < 0.001).
This table shows molecular features associated with STK39 in patient tissues and cancer cell lines. In patient samples, STK39 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, STK39 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
